Rocket Pharmaceuticals Inc (RCKT) - Net Assets
Based on the latest financial reports, Rocket Pharmaceuticals Inc (RCKT) has net assets worth $313.67 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($368.03 Million) and total liabilities ($54.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RCKT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $313.67 Million |
| % of Total Assets | 85.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | -8.0% |
| 10-Year Change | 325.72% |
| Growth Volatility | 99.91 |
Rocket Pharmaceuticals Inc - Net Assets Trend (2012–2024)
This chart illustrates how Rocket Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore RCKT total asset value for the complete picture of this company's asset base.
Annual Net Assets for Rocket Pharmaceuticals Inc (2012–2024)
The table below shows the annual net assets of Rocket Pharmaceuticals Inc from 2012 to 2024. For live valuation and market cap data, see Rocket Pharmaceuticals Inc (RCKT) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $463.23 Million | -5.96% |
| 2023-12-31 | $492.57 Million | +0.59% |
| 2022-12-31 | $489.69 Million | +7.69% |
| 2021-12-31 | $454.72 Million | -9.69% |
| 2020-12-31 | $503.52 Million | +63.85% |
| 2019-12-31 | $307.30 Million | +58.37% |
| 2018-12-31 | $194.04 Million | +306.24% |
| 2017-12-31 | $47.76 Million | -34.72% |
| 2016-12-31 | $73.17 Million | -32.76% |
| 2015-12-31 | $108.81 Million | +311.05% |
| 2014-12-31 | $-51.56 Million | -32.56% |
| 2013-12-31 | $-38.90 Million | -25.75% |
| 2012-12-31 | $-30.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rocket Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 110722200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.06 Million | 0.23% |
| Other Comprehensive Income | $66.00K | 0.01% |
| Other Components | $1.68 Billion | 362.71% |
| Total Equity | $463.23 Million | 100.00% |
Rocket Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Rocket Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Airnet Technology Inc
NASDAQ:ANTE
|
$385.29 Million |
|
GnCenergy Co Ltd
KQ:119850
|
$385.55 Million |
|
Guangdong Failong Crystal Technology Co Ltd
SHE:300460
|
$385.84 Million |
|
Yung Chi Paint & Varnish Mfg Co Ltd
TW:1726
|
$385.85 Million |
|
Jiangsu Chuanzhiboke Education Tech
SHE:003032
|
$385.15 Million |
|
THARISA NON LIST. DL-001
F:7YZ
|
$385.14 Million |
|
EQV Ventures Acquisition Corp.
NYSE:EQV
|
$385.09 Million |
|
Dipula Income Fund Ltd
JSE:DIB
|
$385.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rocket Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 492,574,000 to 463,234,000, a change of -29,340,000 (-6.0%).
- Net loss of 258,746,000 reduced equity.
- New share issuances of 185,739,000 increased equity.
- Other comprehensive income decreased equity by 253,000.
- Other factors increased equity by 43,920,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-258.75 Million | -55.86% |
| Share Issuances | $185.74 Million | +40.1% |
| Other Comprehensive Income | $-253.00K | -0.05% |
| Other Changes | $43.92 Million | +9.48% |
| Total Change | $- | -5.96% |
Book Value vs Market Value Analysis
This analysis compares Rocket Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-14.70 | $3.56 | x |
| 2013-12-31 | $-18.49 | $3.56 | x |
| 2014-12-31 | $-24.51 | $3.56 | x |
| 2015-12-31 | $16.47 | $3.56 | x |
| 2016-12-31 | $10.95 | $3.56 | x |
| 2017-12-31 | $7.06 | $3.56 | x |
| 2018-12-31 | $4.93 | $3.56 | x |
| 2019-12-31 | $6.27 | $3.56 | x |
| 2020-12-31 | $9.09 | $3.56 | x |
| 2021-12-31 | $7.19 | $3.56 | x |
| 2022-12-31 | $7.19 | $3.56 | x |
| 2023-12-31 | $5.86 | $3.56 | x |
| 2024-12-31 | $4.89 | $3.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rocket Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -55.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-55.86%) is below the historical average (-35.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.96 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.73 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.38 Million |
| 2015 | -62.48% | 0.00% | 0.00x | 1.04x | $-78.86 Million |
| 2016 | -58.57% | 0.00% | 0.00x | 1.77x | $-50.17 Million |
| 2017 | -61.76% | 0.00% | 0.00x | 2.13x | $-34.27 Million |
| 2018 | -38.40% | 0.00% | 0.00x | 1.30x | $-93.92 Million |
| 2019 | -27.08% | 0.00% | 0.00x | 1.21x | $-113.96 Million |
| 2020 | -29.13% | 0.00% | 0.00x | 1.17x | $-197.02 Million |
| 2021 | -37.18% | 0.00% | 0.00x | 1.09x | $-214.54 Million |
| 2022 | -45.31% | 0.00% | 0.00x | 1.13x | $-270.83 Million |
| 2023 | -49.86% | 0.00% | 0.00x | 1.15x | $-294.85 Million |
| 2024 | -55.86% | 0.00% | 0.00x | 1.14x | $-305.07 Million |
Industry Comparison
This section compares Rocket Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rocket Pharmaceuticals Inc (RCKT) | $313.67 Million | 0.00% | 0.17x | $385.27 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (… Read more